Kornimate/medical-research-clean huggingface dataset:
action modules on resilience and psychological health

Conditions: Stroke Patients

Summary: this study aimed to determine whether interventions that use the specific thematic nursing care action modules (stnc-am) platform improve patients' psychological health over a two-month period.

the stnc-am platform that investigator present here is an educational program that integrates education and coaching. stnc-am has six key aspects: stroke prevention, management of emotions, management of fatigue, physical activity, caregiver training, and integrative resources. each scope contains detailed care guidance. the nurse coaching component was based on the six key aspects detailed above. this online platform can guide nurses' health education for the comprehensive care of stroke patients.

Eligibility criteria:
inclusion criteria: * remaining hospitalized within 6 months after a stroke attack. * being able to communicate verbally. * being willing to participate. exclusion criteria: * aphasia

Keywords: anxiety depression resilience illness representation
open label study for the use of transcranial ultrasound treatment of tremor

Conditions: Tremor; Parkinson Disease; Essential Tremor

Summary: the purpose of this phase i open label study is to evaluate longer term tolerability and potential effectiveness of transcranial ultrasound in people with tremor as a results of parkinson's disease or essential tremor.

this study is designed to evaluate the safety and efficacy of focused ultrasound in patients with parkinson's disease or essential tremor characterized by tremor. the safety of this protocol will be closely monitored and data will be used to determine whether any significant safety issues exist when using focused ultrasound. adverse events will be noted whenever they occur but will be recorded at the time of the procedure and throughout routine follow-ups, which will persist weekly throughout the duration of the active study protocol. patients deemed potentially appropriate candidates for focused ultrasound therapy will be treated with 8 sessions of transcranial ultrasound, each of which consists of 10 to 30 minutes of active administration. clinical and safety outcome measures will be obtained throughout and after completion of the study protocol.

Eligibility criteria:
inclusion criteria: in order for a subject to be considered for the essential tremor application of this study, the following criteria are required: subjective complaint of tremor assessed and validated by physician must be willing to comply with the study protocol english proficiency at least 18 years of age at most 90 years of age in order for a subject to be considered for the parkinson's disease application of this study, the following criteria are required: diagnosis of parkinson's disease validated by physician must be willing to comply with the study protocol english proficiency at least 18 years of age at most 90 years of age exclusion criteria: in order for a subject to be considered for this study, he/she may not have any of the following: subjects not english proficient subjects unable to give informed consent subjects do not meet age requirements (18-90) subjects who would not be able to lay down without excessive movement in a calm environment sufficiently long enough to be able to achieve sleep pregnancy, women who may become pregnant or are breastfeeding women with child-bearing potential who are not willing to use a double-barrier birth control method males not willing to use a double-barrier birth control method with female sex partners with child-bearing potential advanced terminal illness any active cancer or chemotherapy any other neoplastic illness or illness characterized by neovascularity macular degeneration subjects with scalp rash or open wounds on the scalp (for example from treatment of squamous cell cancer)
efficacy and safety study of neramexane to treat congenital and acquired nystagmus

Conditions: Nystagmus, Congenital Idiopathic; Nystagmus, Acquired

Summary: the purpose of this study is to investigate the safety and efficacy of neramexane mesylate in the treatment of congenital idiopathic nystagmus (cin) in comparison to placebo. in addition, a subgroup of multiple sclerosis (ms) patients suffering from acquired nystagmus will be included; this subgroup will be analyzed in an exploratory manner only.


Eligibility criteria:
inclusion criteria: * patients with congenital idiopathic nystagmus or acquired nystagmus subsequent to multiple sclerosis * male or female outpatients * aged between 18 and 80 years (inclusive) at screening exclusion criteria: * patients with evidence of neurologic disorders other than cin such as congenital nystagmus due to albinism or retinal diseases and/or acquired nystagmus (exemption: secondary to ms)
efficacy study of maintenance it-101 therapy for ovarian cancer patients.

Conditions: Cancer; Ovarian Cancer; Solid Tumor

Summary: this study will assess the effect of it-101 on delaying cancer progression in patients with platinum sensitive ovarian cancer.


Eligibility criteria:
key inclusion criteria: * women between the age of 18 and 78, inclusive; * evidence of platinum-sensitive ovarian cancer following the patient's primary treatment(\>= 6 months); * received a 2nd line platinum-based chemotherapy regimen (4-6 cycles) without evidence of progression; * may have measurable or unmeasurable disease; * eastern cooperative oncology group (ecog) 0 or 1; * ability to understand and the willingness to sign a written informed consent document. key exclusion criteria: * women who are pregnant or lactating; * prior treatment with a topoisomerase inhibitor; * patients with unacceptable organ and/or hematologic reserve at screening; * urine protein of \> 500 mg/day or active nephropathy; * electrocardiogram (ecg) with evidence of clinically significant conduction abnormalities or active ischemia as determined by the investigator; * history of pancreatitis within the last 12 months; * patients treated with previous high dose chemotherapy or stem cell transplant within the last 5 years; * use of any investigational agents within 4 weeks of study enrollment; * uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, psychiatric illness or other co-morbidity that presents a risk to the patient as determined by the investigator.

Keywords: cancer neoplasms solid tumor ovarian cancer solid malignancies
management and outcome of scorpion sting in children

Conditions: Scorpion Stings

Summary: to determine the clinical characteristics of children with scorpion sting and implement guidelines for management of those children and observe the outcome

scorpion envenomation is a severe,sometimes fatal medical condition especially in children .worldwide,there are more than 1.2 million scorpion stings each year,mostly in tropical and subtropical regions.every year,more than 420,000 snake bite,scorpion sting and spider bite incidents occur in the middle east and north africa (mena).in the region of assiut,in the south of egypt,the annual incidence and mortality by scorpion stings has been reported to be 88 and 5.5 per 100,000 inhabitants.there are 1500 sub species of scorpions in the globe,and 50 of those have venom that is harmful to humans.the most toxic scorpion families are the buthidae family.the mena region is home to 27 species of scorpions from three families:thebuthidae,hemiscorpiidae,and scorpionidae.significant morbidity and mortality are caused by scorpion stings .in addition to local effectslikeredness,pain,burning,and swelling,scorpion venom exhibits variability among sub species and has a complex structure made up of neurotoxic proteins,salts,acidic proteins,and organic compounds.these components can cause neurological,cardiovascular,hematologic,and renal side effects.because scorpion venoms are complex mixtures of several toxins,including cardiotoxins,nephrotoxins,hemolytictoxins,and neurotoxins,there is a possible danger of developing severe and frequently deadly clinical consequences.heart failure and pulmonary edema are the main causes of mortality .as regards management of scorpion sting early antivenom treatment is recommended but its value remains controversial as it may cause anaphylactic reactions .furthermore the majority of cases need supportive treatment to alleviate the cardiovascular effect.cardiovascular symptoms respond well to vasodilators such as alpha-1blockers like prazosin.prazosinis considered a physiological and pharmacological antidote to scorpion venom action.it antagonizes the after-effects of venom-liberated catecholamines.since the use of prazosin with antivenom the recovery from scorpion sting has been hastened and mortality rate has been reduced from 30% to 1%.uptill now there are no guidlines implemented at our hospital for the management of scorpion sting so that our study will aim at implementing guidelines for management of children with scorpion sting and observe the outcome of those children.the guidelines used are those recommended from the egyptian ministry of health and population with the addition of prazosin as many studies have concluded the benefits of prazosin

Eligibility criteria:
inclusion criteria: - all children under 18 years with definite history of scorpion sting exclusion criteria: * children with no definite history of sting or more than 18 years
drug interaction study with proton pump inhibitor

Conditions: HIV Infections

Summary: the purpose of this clinical research study is to assess the effect of omeprazole at 20 mg on the pharmacokinetics of atazanavir administered as atazanavir with ritonavir relative to atazanavir or atazanavir/ritonavir in the absence of omeprazole in healthy subjects.


Eligibility criteria:
inclusion criteria: * healthy male and female subjects between the ages of 18 to 50 years old with bmi 18 to 32 kg/m2

Keywords: protease inhibitor
hepcidin mimetic in patients with polycythemia vera (revive)

Conditions: Polycythemia Vera

Summary: this is a phase 2 study with an open-label dose escalation phase followed by a blinded withdrawal phase and an open label extension. the study is designed to monitor the ptg-300 safety profile and to obtain preliminary evidence of efficacy of ptg-300 for the treatment of phlebotomy-requiring polycythemia vera.

phase 2 study in approximately sixty subjects previously diagnosed with polycythemia vera who require phlebotomy on a routine basis. there is a 28 week dose finding phase to identify a dose that maintains hematocrit \<45%. subjects who successfully complete the dose finding phase will be entered into a 12 week randomized withdrawal phase to confirm the response. subsequently patients will enter into an up to 3 year open label extension to investigate long term safety.

Eligibility criteria:
main inclusion criteria: all subjects must meet all of the following inclusion criteria to be enrolled. 1. male and female subjects aged 18 years or older. 2. meet revised 2016 world health organization (who) criteria for the diagnosis of polycythemia vera. 3. records of all phlebotomies performed for at least 28 weeks (preferably up to 52 weeks) before dosing are available. 4. subjects who are not receiving cytoreductive therapy must have been discontinued from any prior cytoreductive therapy for at least 24 weeks before screening and have recovered from any adverse events due to cytoreductive therapy. 5. subjects receiving cytoreductive therapy with hydroxyurea, interferon, or ruxolitinib must have received cytoreductive therapy for at least 24 weeks and be on a stable dose or have a decreasing dose (medical monitor approval required) for at least 8 weeks before dosing and with no planned change in dose. main exclusion criteria: subjects must meet none of the following exclusion criteria to be enrolled: 1. active or chronic bleeding within 4 weeks of screening. 2. meets the criteria for post-pcv myelofibrosis as defined by the international working group-myeloproliferative neoplasms research and treatment (iwg-mrt). 3. known primary or secondary immunodeficiency. 4. any surgical procedure requiring general anesthesia within 1 month prior to screening or planned elective surgery during the study.

Keywords: polycythemia vera
environmental factors to increase patient comfort during urodynamics testing

Conditions: Lower Urinary Tract Symptoms; Urologic Diseases

Summary: urodynamics is a comprehensive study of the lower urinary tract. although the information obtained from urodynamics answers several questions and assists in guiding therapies for patients, the testing environments is unnatural and may be distressing for patients. this may impact the results of the study, as it is not uncommon for patients to be unable to void for the test due to their distress. often to alleviate the distress, music or soothing noises are used in the background. the study aims to identify simple environmental factors which may improve patient experience with urodynamic testing. the population will include patients with existing appointments for urodynamics testing at the mayo urology clinic. the investigators plan to assess patient satisfaction and comfort during this assessment using a visual analog scale questionnaire. the environmental variables will include music of the patients' preference, the sound of running water, or no background noise at all. by asking patients to complete a questionnaire, the investigators will be able to assess ways to improve patient comfort in a commonly used urologic assessment.


Eligibility criteria:
inclusion criteria: * all adults undergoing urodynamics * must be able to understand and complete questionnaire exclusion criteria:
safety and efficacy of triple combination therapy in patients with primary open-angle glaucoma or ocular hypertension

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: this study will evaluate the safety and efficacy of triple combination therapy compared with fixed combination brimonidine tartrate/timolol ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension.


Eligibility criteria:
inclusion criteria: * ocular hypertension or primary open-angle glaucoma in each eye * requires treatment with iop-lowering medication in both eyes exclusion criteria: * required chronic use of ocular medications during the study other than study medication * use of any corticosteroids within 30 days * history of any prior eye surgery, except for uncomplicated eye surgery performed more than 6 months before the screening visit * anticipated wearing of contact lenses during the study
physical exercise versus rosiglitazone in cad and prediabetes

Conditions: Impaired Glucose Tolerance

Summary: the aim of this study is to prospectively assess the relative benefits of either treatment with rosiglitazone or physical exercise on endothelial function in patients with impaired fasting glucose or impaired glucose tolerance and coronary artery disease (cad).


Eligibility criteria:
inclusion criteria: * impaired fasting glucose or impaired glucose tolerance * angiographic evidence of coronary artery disease exclusion criteria: * diabetes mellitus type i or ii * preexisting antidiabetic medication * unstable angina * indication for coronary bypass surgery * significant left main disease * myocardial infarction within preceding 3 months * ejection fraction \< 40% * significant heart valve disease * severe metabolic disorders * severe disorders in lipoprotein metabolism * thyroid disorders * alcohol or drug abuse * pregnancy * participation in another trial
liver fat content and bariatric surgery

Conditions: Non-Alcoholic Fatty Liver Disease; Bariatric Surgery; Magnetic Resonance Imaging

Summary: on the basis of previous research, this subject intends to evaluate the liver improvement of patients with liver disease after weight loss by mri, and quantify it by extracting features, so as to provide a new method to judge the liver status of patients with liver disease, and to evaluate the correlation between the inflammatory status of patients and the quantitative features of mri, and try to explain the reasons for the improvement of fatty liver status of patients with liver disease after weight loss. to provide a new theoretical basis for fatty liver and systemic inflammatory liver damage in patients with liver disease after weight loss surgery, and to link them, and try to explain the improvement of fatty liver in patients with liver disease through the reduction of systemic inflammatory level.

this study is a prospective study to explore the improvement of fatty liver and severe state of the whole body in patients with liver disease undergoing weight-loss surgery. the research object is obese patients who underwent laparoscopic sleeve gastrectomy in our hospital. according to the standard of accepting the discharge, about 50 patients were selected and divided into groups according to preoperative, postoperative one month, postoperative three months and postoperative six months.all patients underwent routine sequence examinations using a siemens 3.0t mri scanner (magnetom prisma, siemens healthcare, munich, germany).this study investigates alterations in nafld among patients with obesity who underwent bariatric surgery using mri-pdff and mrs techniques. additionally, we evaluated the factors that may influence these changes in patients after the surgical procedure.

Eligibility criteria:
inclusion criteria: * 16 years old \< age \< 60 years old * bmi \> 32kg/m2 * no previous drinking history; weekly drinking of males \< 210g and females \< 140g in 12 months * preoperative auxiliary examination supports the diagnosis of fatty liver, and liver mri examination * previous attempts to lose weight are ineffective * complete case data. exclusion criteria: * secondary obesity * history of drinking or excessive drinking (in the past 12 months, male's weekly alcohol intake was ≥210g, female's weekly alcohol intake was ≥ 140g) * other diseases causing abnormal liver function * body mass index \< 28kg/m2 * poor compliance or self-control, unable to follow the dietary guidance after operation * those who cannot complete the follow-up
the effect of albumin value, halp score, and lcr value on predicting survival and recurrence in patients with pancreatic adenocarcinoma

Conditions: Pancreatic Neoplasms; Pancreas Cancer

Summary: the aim of this study is to investigate whether the albumin value and the ratios of biochemical markers; hemoglobin, albumin, lymphocyte and platelet (halp score) and lymphocyte-c-reactive protein ratio (lcr) can predict the survival and recurrence of the disease in patients with pancreatic adenocarcinoma.


Eligibility criteria:
inclusion criteria: * whipple operation and total pancreatectomy due to pathologically confirmed pancreatic adenocarcinoma exclusion criteria: * patients with other malignant tumors (choledochal tumor, papilla tumor and duodenal tumor)

Keywords: pancreatic adenocancer albumin hemoglobin lymphocyte platelet
selection protocol for liver transplantation in patients aged over 70 years

Conditions: End Stage Liver DIsease; Liver Transplantation; Old Age

Summary: increased life expectancy and aging population has led to a trend of increasing liver transplant (lt) volume in the elderly. nowadays, advanced age is not considered an absolute contraindication for lt but elderly lt candidates typically have an age-associated burden of comorbid conditions that can pose several clinical challenges during the selection/evaluation process for lt. specific algorithms for elderly patient selection for lt are not well established; however, consensus agreement is that elderly lt candidates need a more rigorous selection process. this study proposes a "step by step" algorithm of selection for liver transplant candidates more than 70 years.


Eligibility criteria:
inclusion criteria: * age \>70 years and ≤ 75 years * liver transplant from cadaveric donor * first liver transplant * end stage liver disease or liver tumor exclusion criteria: * age ≤ 70 years * living donor liver transplant * previous liver transplant * liver transplant for acute liver failure

Keywords: liver transplantation old recipients age>70 years
optimal timing of parasternal intercostal nerve block application for acute pain management in cardiac surgery

Conditions: Pain, Acute

Summary: patients experiencing pain after undergoing cardiac surgery may also experience prolonged immobilization, insufficient respiratory functions, and the inability to cough due to median sternotomy. therefore, duration of mechanical ventilation, length of intensive care unit (icu) stay, and length of hospital stay of these patients will increase significantly. many facial plane blocks have been introduced as simple and safe intervention for thoracic wall anesthesia and analgesia. parasternal intercostal nerve block (psib) is a "superficial block" which involves local anesthetic (la) infiltration in the intercostal space around the sternum where the anterior branches of intercostal nerves exist. intraoperative la administration under direct vision of the surgeon ensures adequate delivery of drugs and minimizes bleeding complication or inadvertent administration in blood vessels. meanwhile, preoperative administration of la guided by ultrasound imaging has been used in variable surgical settings with noticeable success because of preemptive inhibition of noxious stimuli.


Eligibility criteria:
inclusion criteria: * age from 20-70 years, * scheduled to undergo elective cardiac surgeries through median sternotomy involving cardiopulmonary bypass (cpb). exclusion criteria: * patients requiring preoperative inotropes, mechanical ventilation or intra-aortic balloon pump, * patients who have previous cardiac surgery, * prolonged cpb time (cpb\>120 minutes), * intubation time more than 12hrs or planned for overnight ventilation. * allergy to any of used drugs, * opioids addiction, * chronic liver disease, chronic renal disease, and cognitive impairment.